Latest Industry Insights

There remains an active debate within the psychedelic community about the importance of psychedelic experiences to these drugs’ therapeutic effects. Delix Therapeutics is developing compounds, called psychoplastogens, that act similarly to psychedelic compounds at the molecular level but do not induce hallucinations. We spoke with the Delix team to find out more about their research's progress.

In this interview, CEO of Arrayjet Dr. Iain McWilliam discusses advancements in modern microarray technology and the benefits that these tools can provide for high-throughput screening.

This article spotlights the driving forces behind Basel’s snowballing reputation, and notes some of the success stories arising from this innovative biotech powerhouse.

In this interview, we learn more about the support available for entrepreneurs looking to take their ideas from the bench to viable business.

In this opinion piece, Daniel Elgort takes a look at how bioinformatics has already shaped the cancer care landscape and how its role will continue to grow over time.

This article discusses the importance of data lineage and traceability for academic labs looking to maximize their publishing potential.

In this article, we explore how equipment, laboratory and experimental approaches can accelerate failure so companies change and adjust their approach before it’s too late.

This article walks through the fundamentals of CRISPR screening and its most exciting applications, including unpicking cellular signaling networks, discovering how viruses like COVID-19 infect our cells and finding new drug targets.

This article discusses an innovative biofabrication method that uses a single 3D hydrodynamic flow focusing chip to generate different hydrogel configurations with specific geometries for various biological applications.

Only 10 years ago, Nobel prize-winning work introduced CRISPR as a new and powerful genome editing tool. Here, three noteworthy applications of the technology are highlighted.